Á¦38Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö : 2018-11-16 ±³À°ÀÏÀÚ : 2018-11-16 ±³À°Àå¼Ò : °¸ª¾¾¸¶Å©È£ÅÚ ¾Æ»êÆ®¸®¿ò ±³À°ÁÖÁ¦ : Á¦38Â÷ ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ Ãß°èÇмú½ÉÆ÷Áö¾ö ÁÖÃÖ±â°ü : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ ´ã´çÀÚ : ´ëÇÑ·ù¸¶Æ¼½ºÇÐȸ ¿¬¶ôó : 02-794-2630 À̸ÞÀÏ : webmaster@rheum.or.kr ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Á¤Çü¿Ü°ú, Áø´Ü°Ë»çÀÇÇаú Âü¼®¿¹»óÀοø : 300¸í Èñ¸ÁÆòÁ¡ : 6Á¡ Áö¿ª : °¿øµµ ±³À°½Ã°£ : 11 ½Ã°£ 40ºÐ ¼¼ºÎ¼ö°·á : 60,000¿ø ºñ°í : ȸ¿ø Àü¹®ÀÇ, ÀüÀÓÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø »çÀüµî·Ï 60,000¿ø, ÇöÀåµî·Ï 80,000¿øȸ¿ø Àü°øÀÇ, °£È£»ç, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø ¿Ü »çÀüµî·Ï 40,000¿ø, ÇöÀåµî·Ï 60,000¿øºñȸ¿ø Àü¹®ÀÇ, ÀüÀÓÀÇ, ¹Ú»ç±Þ ¿¬±¸¿ø »çÀüµî·Ï 80,000¿ø, ÇöÀåµî·Ï 100,000¿øºñȸ¿ø Àü°øÀÇ, °£È£»ç, ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø ¿Ü »çÀüµî·Ï 50,000¿ø, ÇöÀåµî·Ï 70,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ ±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 09:00~09:30 Validation of FRAX for osteoporosis treatment decision in patients with osteoarthritis: A multicenter comparative study of FRAX criteria and WHO criteria ±èº¸¿µ(¿ï»êÀÇ´ë) ±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 09:30~10:00 Angiogenesis using smart material ±è¼º°ï(°¸ª¿øÁÖ´ë Ä¡´ë ±¸°¾Ç¾È¸é¿Ü°úÇÐ) ±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 10:00~10:30 õ¿¬¹°À» ÀÌ¿ëÇÑ °ñ´Ù°øÁõ Ä¡·áÁ¦ °³¹ß À¯ÁöÇý(KIST) ±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 11:00~11:40 Systemic and local fat in knee osteoarthritis. Changhai Ding(Univ. of Tasmania, Australia) ±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 11:20~12:00 Management of systemic sclerosis -current status and future directions Masataka Kuwana(Nippon Medical School, Japan) ±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 12:10~12:40 ICHOM standard set of outcomes that matter to patients suffering from inflammatory arthritis, explaining the goal of ICHOM, the methodology and how to apply this global development Mart A.F.J van de Laar(University of Twente, the Netherlands) ±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 13:30~13:50 What¡¯s the choice after failure of first anti-TNF in RA? Â÷ÈƼ®(¼º±Õ°üÀÇ´ë) ±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 13:50~14:10 To taper or not to taper biologics in RA? ½É½Âö(Ãæ³²ÀÇ´ë) ±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 14:10~14:30 Can we stop progression of structural damage in axial SpA? ±è¿ë±æ(¿ï»êÀÇ´ë) ±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 14:30~14:50 Do we need to supplement vitamin D in autoimmune rheumatic diseases? ±è±ÙÅÂ(°í½ÅÀÇ´ë) ±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 15:30~15:50 New therapy in SLE: is the glass half-full or half-empty? ¼Ã¢Èñ(¾ÆÁÖÀÇ´ë) ±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 15:50~16:10 Can we withdraw Immunosuppressants in patients with lupus nephritis in remission? ¼ºÀ±°æ(ÇѾçÀÇ´ë) ±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 16:10~16:30 Do we still need biopsy to diagnose Sjögren¡¯s syndrome? °û½Â±â(°¡Å縯ÀÇ´ë) ±³À°½Ã°£ 11-16 Room 1 (¹Ù´ÙȦ A, 2F) 16:30~16:50 How can we better manage interstitial lung disease in systemic sclerosis? ÀÌÀººÀ(¼¿ïÀÇ´ë) ±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 09:00~09:30 ÀÓ»óÁø·áÁöħ °³¹ß °³¿ä¿Í ±âȹ ±èÀç±Ô(Áß¾ÓÀÇ´ë, ´ëÇÑÀÇÇÐȸ Á¤Ã¥ÀÌ»ç) ±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 09:30~09:50 Áø·áÁöħ °³¹ß °æÇè-GIOP¿Í ¿¹¹æÁ¢Á¾À» Áß½ÉÀ¸·Î ÀüÂùÈ«(¼øõÇâÀÇ´ë) ±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 09:50~10:05 Áø·áÁöħ °³¹ß Çʿ伺-·ù¸¶Æ¼½º °üÀý¿° ÀÌÁö¼ö(ÀÌÈÀÇ´ë) ±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 10:05~10:20 Ã༺ôÃß°üÀý¿°-°Á÷ôÃß¿° Ä¡·á±Ç°í °³¹ß ¹éÇÑÁÖ(°¡ÃµÀÇ´ë) ±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 13:30~14:00 Is it possible to prevent RA? ÀÌ»óÀÏ(°æ»óÀÇ´ë) ±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 14:00~14:30 The cellular and molecular mechanisms in cartilage degeneration Çѽ¿ì(°æºÏÀÇ´ë) ±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 14:30~15:00 CAR-T cells beyond cancer: A new therapy for autoimmune diseases? Á¤ÁØÈ£(¼¿ïÀÇ´ë »ýÈÇб³½Ç) ±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 15:30~16:00 Epigenetic control of immune cells. ±è¶ô±Õ(¿¬¼¼ÀÇ´ë ÀÇ»ý¸í°úÇкÎ) ±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 16:00~16:30 Follicular helper T cell. ÃÖÀ±¼ö(¼¿ïÀÇ´ë ÀÇ°úÇаú) ±³À°½Ã°£ 11-16 Room 2 (¹Ù´ÙȦ B, 2F) 16:30~17:00 Chronic/persistent infection and autoimmune diseases ÃÖ¿µ´Ô(¼¿ïÄ¡Àü¿ø ±¸°¹Ì»ý¹°Çб³½Ç) ±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 13:30~13:50 ·ù¸¶Æ¼½º°üÀý¿°ÀÇ Áúº´È°¼ºµµ ÃøÁ¤. ÀÌâÈÆ(¿ø±¤ÀÇ´ë) ±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 13:50~14:10 °Á÷ôÃß¿°ÀÇ Áúº´È°¼ºµµ ÃøÁ¤. ÀÌ»ó¿ø(¿¬¼¼ÀÇ´ë) ±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 14:10~14:30 °í½ÄÀû ÇÕ¼º Ç×·ù¸¶Æ¼½ºÁ¦Á¦(csDMARDs) ¾Ë¾Æº¸±â ±èÇö¼÷(¼øõÇâÀÇ´ë) ±³À°½Ã°£ 11-16 Room 3(ÇÏ´ÃȦ, 3F) 14:30~14:50 ·ù¸¶Æ¼½º ÁúȯÀÇ Ç¥ÀûÄ¡·áÁ¦. È«½ÂÀç(°æÈñÀÇ´ë)
|